PRTK News and Press, Paratek Pharmaceuticals Inc. From 10/27/20

BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, go...

BOSTON, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...

Investment Thesis Reviewing Paratek Pharmaceuticals ( PRTK ) - a commercial-stage biopharmaceutical company with 2 approved antibiotic products, Nuzyra and Seysara - I am inclined to believe that there is a reasonably strong case for investment. The antibiotics market offers unfavourable m...

Gainers:  Yield10 Bioscience (NASDAQ: YTEN ) +60% . More news on: Yield10 Bioscience, Inc., Renren Inc., Virtusa Corporation, Stocks on the move, , Read more ...

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, go...

Paratek Pharmaceuticals, Inc. (PRTK) Q2 2020 Earnings Conference Call August 10, 2020 08:30 AM ET Company Participants Ben Strain - Vice President, Investor Relations and Corporate Communications Evan Loh - Chief Executive Officer Adam Woodrow - President and Chief Commercial Off...

The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Paratek Pharmaceuticals (NASDAQ: PRTK ) : Q2 GAAP EPS of -$0.53 misses by $0.47 . Revenue of $9.3M (+353.7% Y/Y) misses by $28.73M . Press Release More news on: Paratek Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

-- Paratek Raises Full Year 2020 Revenue Guidance; Total   Revenue guidance expected to be Between $78  and $83 Million Driven by Strong NUZYRA Net Revenue -- Company Lowering 2020 R&D and SG&A Expense Guidance...

BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, go...